Evidence map›Paper›PMID 34442334›Full record

ArticleJournal of personalized medicine2021

Functional Characterization of 21 Rare Allelic

Masaki Kumondai, Evelyn Marie Gutiérrez Rico, Eiji Hishinuma, Yuya Nakanishi, Shuki Yamazaki, Akiko Ueda, Sakae Saito, Shu Tadaka, Kengo Kinoshita, Daisuke Saigusa and 4 more

Open access · goldAbstract read
In one paragraph

Article in Journal of personalized medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Masaki KumondaiLaboratory of Pharmacotherapy of Life-Style Related Diseases, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai 980-8578, Japan.ORCID 0000-0002-2333-2847
Evelyn Marie Gutiérrez RicoLaboratory of Pharmacotherapy of Life-Style Related Diseases, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai 980-8578, Japan.
Eiji HishinumaAdvanced Research Center for Innovations in Next-Generation Medicine, Tohoku University, Sendai 980-8575, Japan.
Yuya NakanishiLaboratory of Pharmacotherapy of Life-Style Related Diseases, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai 980-8578, Japan.
Shuki YamazakiLaboratory of Pharmacotherapy of Life-Style Related Diseases, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai 980-8578, Japan.
Akiko UedaAdvanced Research Center for Innovations in Next-Generation Medicine, Tohoku University, Sendai 980-8575, Japan.
Sakae SaitoAdvanced Research Center for Innovations in Next-Generation Medicine, Tohoku University, Sendai 980-8575, Japan.
Shu TadakaTohoku Medical Megabank Organization, Tohoku University, Sendai 980-8575, Japan.
Kengo KinoshitaTohoku Medical Megabank Organization, Tohoku University, Sendai 980-8575, Japan.
Daisuke SaigusaTohoku Medical Megabank Organization, Tohoku University, Sendai 980-8575, Japan.
Tomoki NakayoshiFaculty of Pharmacy, Meijo University, Nagoya 468-8503, Japan.
Akifumi OdaFaculty of Pharmacy, Meijo University, Nagoya 468-8503, Japan.
Noriyasu HirasawaLaboratory of Pharmacotherapy of Life-Style Related Diseases, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai 980-8578, Japan.
Masahiro HiratsukaLaboratory of Pharmacotherapy of Life-Style Related Diseases, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai 980-8578, Japan.ORCID 0000-0002-3767-7686
Tohoku University · JPMeijo University · JP

Funding

Japan Agency for Medical Research and Development 21kk0305009Japan Agency for Medical Research and Development JP20km0105001Japan Agency for Medical Research and Development JP20km0105002Japan Agency for Medical Research and Development JP20km0405001Japan Society for the Promotion of Science 19J10744Pharmaceutical Society of Japan N-170603Smoking Research FoundationTakahashi Industrial and Economic Research Foundation
6 · The paper itself

Abstract

Cytochrome P450 1A2 (CYP1A2), which accounts for approximately 13% of the total hepatic cytochrome content, catalyzes the metabolic reactions of approximately 9% of frequently used drugs, including theophylline and olanzapine. Substantial inter-individual differences in enzymatic activity have been observed among patients, which could be caused by genetic polymorphisms. Therefore, we functionally characterized 21 novel CYP1A2 variants identified in 4773 Japanese individuals by determining the kinetic parameters of phenacetin

Indexed as

cytochrome P450 1A2drug metabolismgenetic variationphenacetin

Identifiers

PMID34442334
PMCPMC8401128
OpenAlexW3186728171

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.